Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fluocinolone acetonide intravitreal · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Fluocinolone acetonide | EXPERIMENTAL | Intravitreal fluocinolone acetonide implant |
| Standard care | ACTIVE_COMPARATOR | Standard of Care |
| Fluocinolone acetonide 0.59mg | EXPERIMENTAL | Fluocinolone acetonide ocular implant 0.59mg |
| Fluocinolone acetonide 2.1mg | EXPERIMENTAL | Fluocinolone acetonide ocular implant 2.1mg |
| No intervention | NO_INTERVENTION | Fellow eye |
| Name | Type | Description |
|---|---|---|
| fluocinolone acetonide intravitreal implant | DRUG | surgical intravitreal implant of fluocinolone acetonide |
| corticosteroids and immunosuppressants | DRUG | Systemic corticosteroids alone or combined with immunosuppressants |
| Fluocinolone acetonide 2.1mg | DRUG | Fluocinolone acetonide ocular implant 2.1mg |
Inclusion Criteria: * Males and non-pregnant females at least 6 years of age * History of recurrent unilateral or asymmetric non-infectious posterior uveitis of at east 1 year duration not associated with significant systemic activity of the disease * The more severely affected eye having had at le...
Fluocinolone acetonide intravitreal is an investigational small molecule being studied for the treatment of noninfectious posterior uveitis and non-infectious uveitis, which are inflammatory conditions affecting the eye. It is administered as an intravitreal implant and is currently in Phase 2 clinical development.
Fluocinolone acetonide intravitreal is a corticosteroid that works by reducing inflammation in the eye. It is designed to be implanted directly into the vitreous humor to deliver sustained release of the medication locally, targeting the inflammatory processes involved in uveitis.
Fluocinolone acetonide intravitreal is being developed by Bausch + Lomb Corporation, a company listed on the stock exchange under the ticker symbol BLCO. The company is conducting clinical trials to evaluate the safety and efficacy of this intravitreal implant for uveitis.
Fluocinolone acetonide intravitreal is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to assess its safety and efficacy for treating noninfectious uveitis.
Fluocinolone acetonide intravitreal has been studied in two completed Phase 2 clinical trials. The first trial, NCT00407082, enrolled 278 participants with noninfectious posterior uveitis in the United States. The second trial, NCT00468871, enrolled 140 participants with non-infectious uveitis. Both trials included patients aged 6 years and older.
Fluocinolone acetonide intravitreal refers specifically to the intravitreal implant formulation of fluocinolone acetonide being developed by Bausch + Lomb. While fluocinolone acetonide is a known corticosteroid, this particular product is an investigational implant designed for sustained release in the eye, distinct from other formulations.